ELEVEN BIOTHERAPEUTICS, INC. (NASDAQ:EBIO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
John J. McCabe, the Companys Chief Financial Officer, entered
into an amendment to the Retention Letter Agreement, dated
September 20, 2016, by and between the Company and Mr. McCabe
(the Amendment). The Amendment extends the retention benefits
granted to Mr. McCabe by a period of six months.
qualified in its entirety by reference to the Amendment, which is
filed as Exhibit 10.1 hereto and incorporated herein by
reference.
|
Exhibit No.
|
Description
|
|
10.1
|
Amendment to Retention Letter Agreement, dated March 5,
2017, by and between Eleven Biotherapeutics, Inc. and John J. McCabe. |
About ELEVEN BIOTHERAPEUTICS, INC.> (NASDAQ:EBIO)
Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis. The Company’s therapeutic approach is based on the role of cytokines in diseases of the eye, its understanding of the structural biology of cytokines and its ability to design and engineer proteins to modulate the effects of cytokines. The Company is developing EBI-031 as an intravitreal injection for DME and uveitis. In addition to EBI-031, the Company has another product candidate in early preclinical development, which is designed to block vascular endothelial growth factor (VEGF). ELEVEN BIOTHERAPEUTICS, INC.> (NASDAQ:EBIO) Recent Trading Information
ELEVEN BIOTHERAPEUTICS, INC.> (NASDAQ:EBIO) closed its last trading session up +0.07 at 1.91 with 184,051 shares trading hands.